<?xml version='1.0' encoding='utf-8'?>
<document id="25656737"><sentence text="Sunitinib tissue distribution changes after coadministration with ketoconazole in mice."><entity charOffset="0-9" id="DDI-PubMed.25656737.s1.e0" text="Sunitinib" /><entity charOffset="66-78" id="DDI-PubMed.25656737.s1.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25656737.s1.e0" e2="DDI-PubMed.25656737.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25656737.s1.e0" e2="DDI-PubMed.25656737.s1.e1" /></sentence><sentence text="Sunitinib is a multitargeted tyrosine kinase inhibitor approved for gastrointestinal stromal tumor (GIST), advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors"><entity charOffset="0-9" id="DDI-PubMed.25656737.s2.e0" text="Sunitinib" /><entity charOffset="29-37" id="DDI-PubMed.25656737.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.25656737.s2.e0" e2="DDI-PubMed.25656737.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25656737.s2.e0" e2="DDI-PubMed.25656737.s2.e1" /></sentence><sentence text=" It is metabolized via CYP3A4 and has low brain penetration due to efflux transporters ABCB1B and ABCG2" /><sentence text=" We studied the interaction with ketoconazole (50 mg/kg), antifungal drug which shares metabolic pathways and efflux transporters, in ICR female mice after oral coadministration (30 min apart) of 60 mg/kg sunitinib (study group) versus sunitinib alone (control group)"><entity charOffset="33-45" id="DDI-PubMed.25656737.s4.e0" text="ketoconazole" /><entity charOffset="205-214" id="DDI-PubMed.25656737.s4.e1" text="sunitinib" /><entity charOffset="236-245" id="DDI-PubMed.25656737.s4.e2" text="sunitinib" /><pair ddi="false" e1="DDI-PubMed.25656737.s4.e0" e2="DDI-PubMed.25656737.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25656737.s4.e0" e2="DDI-PubMed.25656737.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25656737.s4.e0" e2="DDI-PubMed.25656737.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25656737.s4.e1" e2="DDI-PubMed.25656737.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25656737.s4.e1" e2="DDI-PubMed.25656737.s4.e2" /></sentence><sentence text=" Plasma, liver, kidney and brain sunitinib concentrations were measured by HPLC at 2, 5, 10, 20, 40 min, 1, 2, 4, 6, 12 h post-sunitinib administration, and non-compartmental pharmacokinetic parameters estimated"><entity charOffset="33-42" id="DDI-PubMed.25656737.s5.e0" text="sunitinib" /></sentence><sentence text=" In plasma, ketoconazole coadministration increased plasma maximum concentration (C MAX) 60 %, delayed time to C MAX (T MAX); 1"><entity charOffset="12-24" id="DDI-PubMed.25656737.s6.e0" text="ketoconazole" /></sentence><sentence text="6-fold greater area under the curve AUC0→∞ (p &lt; 0" /><sentence text="001); lower apparent steady-state volume of distribution (V SS/F) and oral clearance (Cl/F) 40 and 61 %, respectively; and shorter elimination half-life (t 1/2)" /><sentence text=" Sunitinib exhibited extensive tissue distribution which increased after ketoconazole coadministration: total area under the curve (AUC0→∞) increased 1"><entity charOffset="1-10" id="DDI-PubMed.25656737.s9.e0" text="Sunitinib" /><entity charOffset="73-85" id="DDI-PubMed.25656737.s9.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25656737.s9.e0" e2="DDI-PubMed.25656737.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25656737.s9.e0" e2="DDI-PubMed.25656737.s9.e1" /></sentence><sentence text="8-, 2" /><sentence text="8- and 1" /><sentence text="2-fold in kidney, liver and brain, respectively (all p &lt; 0" /><sentence text="001)" /><sentence text=" Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17"><entity charOffset="1-10" id="DDI-PubMed.25656737.s14.e0" text="Sunitinib" /></sentence><sentence text="8 ± 1" /><sentence text="2), kidney (14" /><sentence text="6 ± 1" /><sentence text="52) and brain (2" /><sentence text="25 ± 0" /><sentence text="18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31" /><sentence text="4 ± 4" /><sentence text="7; p &lt; 0" /><sentence text="001), kidney (17" /><sentence text="1 ± 2" /><sentence text="2; p &gt; 0" /><sentence text="05) and decreased in brain (1" /><sentence text="70 ± 0" /><sentence text="23, p &gt; 0" /><sentence text="05)" /><sentence text=" The results showed a significant ketoconazole-sunitinib interaction that affected plasma, tissue pharmacokinetics and tissue uptake mechanisms" /><sentence text=" The study portrays the risk to increase toxicity and potential clinical translatability to treat tumors in tissues" /><sentence text=" " /></document>